FGF2 and fibrosarcoma: Consequently, reduction of tumor vessel density and blood perfusion by combination therapy led to significant increases of tumor hypoxia, which would be otherwise insensitive to anti-VEGF and imatinib monotherapy in FGF-2+ fibrosarcomas (Fig. 4i, j).